International Biotechnology (LON:IBT) Stock Crosses Above 200-Day Moving Average – Here’s What Happened

Posted by Latisha Jones on Feb 19th, 2025

International Biotechnology (LON:IBT – Get Free Report) passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of GBX 691.15 ($8.72) and traded as high as GBX 720 ($9.08). International Biotechnology shares last traded at GBX 712 ($8.98), with a volume of 19,137 shares trading hands.

International Biotechnology Stock Down 0.0 %

The stock has a market capitalization of £255.69 million, a PE ratio of 6.79 and a beta of 0.21. The stock has a fifty day moving average of GBX 702 and a 200-day moving average of GBX 691.15.

International Biotechnology Increases Dividend

The business also recently declared a dividend, which was paid on Friday, January 24th. Shareholders of record on Thursday, December 19th were given a GBX 15.56 ($0.20) dividend. The ex-dividend date of this dividend was Thursday, December 19th. This represents a yield of 2.21%. This is a positive change from International Biotechnology’s previous dividend of $14.50. International Biotechnology’s dividend payout ratio (DPR) is currently 27.67%.

Insider Transactions at International Biotechnology

In other news, insider Katherine Cornish-Bowden acquired 1,500 shares of International Biotechnology stock in a transaction dated Tuesday, December 17th. The shares were acquired at an average cost of GBX 713 ($8.99) per share, for a total transaction of £10,695 ($13,491.86). Corporate insiders own 4.18% of the company’s stock.

About International Biotechnology

(Get Free Report)

The Company’s investment objective is to achieve long-term capital growth by investing in biotechnology and other life sciences companies.

The Company will seek to achieve its objective by investing in a diversified portfolio of companies which may be quoted or unquoted and whose shares are considered to have good growth prospects, with experienced management and strong potential upside through the development and/or commercialisation of a product, device or enabling technology.